Clinical Trials Directory

Trials / Completed

CompletedNCT01307488

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Efficacy of Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy in Patients With Viral Suppression. Randomized, Open-label 96 Weeks Non-inferiority Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
286 (actual)
Sponsor
Fundacion SEIMC-GESIDA · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A switch to a regimen consisting of ATV/RTV 300/100 mg QD + 3TC 300 mg QD in HIV-1 infected subjects in their first antiretroviral regimen and who are virologically suppressed on a regimen which consists of 2 NRTIs + any 3rd agent, is non-inferior to continue or switch to ATV/RTV 300/100 mg QD + 2 optimized NRTIs for maintenance of virological suppression.

Detailed description

Clinical Trial, phase IV, randomized, open label, multicenter with approved drugs in their use conditions. A switch to a regimen consisting of ATV/RTV 300/100 mg QD + 3TC 300 mg QD in HIV-1 infected subjects in their first antiretroviral regimen and who are virologically suppressed on a regimen which consists of 2 NRTIs + any 3rd agent, is non-inferior to continue or switch to ATV/RTV 300/100 mg QD + 2 optimized NRTIs for maintenance of virological suppression.

Conditions

Interventions

TypeNameDescription
DRUGRitonavir boosted Atazanavir + LamivudineATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
DRUGRitonavir boosted Atazanavir + 2 NRTIsATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.

Timeline

Start date
2011-09-01
Primary completion
2014-04-01
Completion
2015-03-01
First posted
2011-03-03
Last updated
2015-05-12

Locations

36 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT01307488. Inclusion in this directory is not an endorsement.